Can A Design Space Be Built On Material Attributes Alone?

Thursday, November 11, 2010: 9:50 AM
Grand Ballroom B (Salt Palace Convention Center)
James N. Michaels1, Holly Bonsignore2, Buffy L. Hudson-Curtis3, Steven Laurenz4, Homer Lin5, Thomas Mathai6, Girish Pande3, Ashlesh Sheth7 and Omar Sprockel8, (1)Merck and Co. Inc., West Point, PA, (2)Pfizer Inc., (3)GlaxoSmithKline, (4)Abbott Laboratories, (5)Amgen, Thousand Oaks, CA, (6)Cephalon, (7)Merck & Co., Inc., (8)Bristol-Myers Squibb Company, New Brunswick, NJ

In April, 2009, the PhRMA Drug Product Technical Group sponsored an industry workshop to explore the practicality and limitations of defining a design space in terms of material attributes rather than process variables. This presentation summarizes and expands on the output of this workshop. A material-attribute design space would be independent of scale and configuration of process equipment and the associated process variables. For this reason, it would be portable in the sense that post-approval changes of equipment scale, nameplate, or location would not require regulatory approval. A hypothetical case study of an immediate release oral tablet is presented to illustrate how such a design space could be constructed and implemented.

Extended Abstract: File Not Uploaded